Drug Manufacturer May Provide Financial Assistance to Patients Traveling to Treatment Centers, OIG Says
- July 11, 2025
The Department of Health and Human Services Office of Inspector General (OIG) said in an advisory opinion posted July 2 that a pharmaceutical manufacturer’s assistance for certain travel, lodging, and associated expenses for qualifying patients receiving its autologous hematopoietic stem-cell based gene therapy could generate prohibited remuneration under the Anti-Kickback Statute (AKS), but will not trigger administrative sanctions.
ARTICLE TAGS
You must be logged in to access this content.